GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OTCPK:HLBBF) » Definitions » EV-to-EBIT

H. Lundbeck AS (H. Lundbeck AS) EV-to-EBIT : 11.56 (As of Jun. 01, 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, H. Lundbeck AS's Enterprise Value is $5,180 Mil. H. Lundbeck AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $448 Mil. Therefore, H. Lundbeck AS's EV-to-EBIT for today is 11.56.

The historical rank and industry rank for H. Lundbeck AS's EV-to-EBIT or its related term are showing as below:

HLBBF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.64   Med: 10.65   Max: 22.79
Current: 11.08

During the past 13 years, the highest EV-to-EBIT of H. Lundbeck AS was 22.79. The lowest was 8.64. And the median was 10.65.

HLBBF's EV-to-EBIT is ranked better than
67.02% of 667 companies
in the Drug Manufacturers industry
Industry Median: 16.63 vs HLBBF: 11.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. H. Lundbeck AS's Enterprise Value for the quarter that ended in Mar. 2024 was $4,623 Mil. H. Lundbeck AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $448 Mil. H. Lundbeck AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 9.69%.


H. Lundbeck AS EV-to-EBIT Historical Data

The historical data trend for H. Lundbeck AS's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS EV-to-EBIT Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 10.04 9.06

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.65 9.95 10.68 9.06 8.87

Competitive Comparison of H. Lundbeck AS's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's EV-to-EBIT falls into.



H. Lundbeck AS EV-to-EBIT Calculation

H. Lundbeck AS's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5180.253/448.194
=11.56

H. Lundbeck AS's current Enterprise Value is $5,180 Mil.
H. Lundbeck AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $448 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


H. Lundbeck AS  (OTCPK:HLBBF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

H. Lundbeck AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=448.194/4623.1648
=9.69 %

H. Lundbeck AS's Enterprise Value for the quarter that ended in Mar. 2024 was $4,623 Mil.
H. Lundbeck AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $448 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


H. Lundbeck AS EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (H. Lundbeck AS) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.